Stock MRNA MODERNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
102 USD -1.39% Intraday chart for Moderna, Inc. -4.68% +2.56%
07:26am China's drugmakers can't sell mRNA shots but haven't quit yet RE
Apr. 16 Moderna Insider Sold Shares Worth $1,575,300, According to a Recent SEC Filing MT

Business Summary

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:

- revenue from product sales (95.7%) ;

- revenues from grants (4%);

- revenues from collaboration agreements (0.3%).

At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.

Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Number of employees: 5,600

Sales per Business

USD in Million2022Weight2023Weight Delta
Messenger RNA (mRNA) Medicines
100.0 %
19,263 100.0 % 6,848 100.0 % -64.45%

Sales per region

USD in Million2022Weight2023Weight Delta
Rest of World
52.5 %
7,298 37.9 % 3,598 52.5 % -50.70%
United States
27.7 %
5,150 26.7 % 1,895 27.7 % -63.20%
Europe
19.8 %
6,815 35.4 % 1,355 19.8 % -80.12%

Managers

Managers TitleAgeSince
Stéphane Bancel CEO
 Chief Executive Officer 51 11-02-28
James Mock DFI
 Director of Finance/CFO 47 22-09-05
Stephen Hoge PSD
 President 48 12-12-31
Brad Miller CTO
 Chief Tech/Sci/R&D Officer - 23-01-02
Jerh Collins CTO
 Chief Tech/Sci/R&D Officer - 22-12-31
Lavina A. Talukdar IRC
 Investor Relations Contact - 19-03-31
Jonathan Hoggatt PRN
 Corporate Officer/Principal - -
José M. Vega PRN
 Corporate Officer/Principal - 21-01-10
Jacqueline Miller PRN
 Corporate Officer/Principal - 20-05-10
Charbel Haber LAW
 General Counsel - 20-04-20

Members of the board

Members of the board TitleAgeSince
Paul Sagan BRD
 Director/Board Member 65 18-05-31
Elizabeth Tallett BRD
 Director/Board Member 74 20-06-30
Francois Nader BRD
 Director/Board Member 67 19-12-10
Noubar Afeyan FOU
 Founder 60 09-12-31
Robert Langer FOU
 Founder 75 09-12-31
Stéphane Bancel CEO
 Chief Executive Officer 51 11-02-28
Sandra Horning BRD
 Director/Board Member 75 20-02-29
Elizabeth Nabel BRD
 Director/Board Member 72 15-11-30
Stephen Berenson BRD
 Director/Board Member 63 17-09-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 382,879,612 346,051,519 ( 90.38 %) 0 90.38 %

Shareholders

NameEquities%Valuation
Baillie Gifford & Co.
11.92 %
45,654,527 11.92 % 4 865 M $
The Vanguard Group, Inc.
10.20 %
39,036,765 10.20 % 4 160 M $
Vanguard Fiduciary Trust Co.
8.856 %
33,907,072 8.856 % 3 613 M $
Stéphane Bancel
5.504 %
21,075,476 5.504 % 2 246 M $
BlackRock Advisors LLC
5.205 %
19,929,660 5.205 % 2 124 M $
STATE STREET CORPORATION
3.819 %
14,623,723 3.819 % 1 558 M $
Robert Langer
3.006 %
11,509,357 3.006 % 1 226 M $
Flagship Pioneering
2.525 %
9,666,038 2.525 % 1 030 M $
Thélème Partners LLP
1.920 %
7,349,456 1.920 % 783 M $
Wellington Management Co. LLP
1.887 %
7,225,579 1.887 % 770 M $

Holdings

NameEquities%Valuation
GENERATION BIO CO.
8.81%
 5,859,375 8.81% 23,847,656 $
METAGENOMI, INC.
4.55%
 1,707,473 4.55% 18,013,840 $
CARISMA THERAPEUTICS, INC.
12.54%
 5,059,338 12.54% 11,484,697 $

Company contact information

Moderna, Inc.

200 Technology Square

02139, Cambridge

+617 714 6500

http://www.modernatx.com
address Moderna, Inc.(MRNA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for Moderna, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
102 USD
Average target price
134.3 USD
Spread / Average Target
+31.67%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+2.56% 39.05B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.82% 41.35B
LONZA GROUP AG Stock Lonza Group AG
+42.78% 40.38B
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 26.67B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+3.09% 24.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.16% 18.36B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+22.12% 11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.74% 11.68B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.75% 11.15B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-19.38% 9.78B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. Company Moderna, Inc.